IIT Bombay Breakthrough: Safer T-Cell Recovery for Cancer Immunotherapy

Researchers at IIT Bombay have developed a novel and more efficient method to recover T-cells grown in the lab for cancer immunotherapies like CAR T-cell treatment. The method uses electrospun scaffolds to better mimic the body's natural environment for cell growth. A key finding is that using the milder enzyme accutase, instead of harsher alternatives like trypsin, leads to higher cell survival and preserves vital surface proteins. This advancement addresses a major practical challenge in making these advanced cellular therapies more viable and effective for patients.

Key Points: IIT Bombay Develops Efficient T-Cell Recovery for Cancer Therapy

  • Safer cell recovery for immunotherapies
  • Electrospun scaffolds mimic body environment
  • Milder enzyme accutase boosts cell survival
  • Preserves key immune signaling proteins
  • Research published in Biomaterials Science
2 min read

IIT Bombay develops method to recover T-cells for cancer therapies

IIT Bombay researchers create a gentler method using electrospun scaffolds and accutase to recover lab-grown T-cells, boosting cancer immunotherapy potential.

"If we want these advanced therapies to reach patients, every step matters. How we grow cells, and how we retrieve them, can make a real difference. - Prof. Prakriti Tayalia"

New Delhi, Feb 5

Researchers at the Indian Institute of Technology Bombay have developed a simpler and more efficient method to recover immune cells grown in the lab for T-cell-based cancer therapies.

In immunotherapies such as CAR T-cell, T-cells (a type of immune cell) are taken from a patient's blood and modified in large numbers in the laboratory and infused back into the patient's bloodstream to help fight cancer.

These cells, grown outside the body, must be collected gently so that they remain alive and functional when returned to the patient. Finding safe and efficient ways to grow T-cells and retrieve them is therefore an important part of making these therapies work.

"Cell recovery sounds simple on paper, but in practice it turns out to be one of the biggest challenges," said Prof. Prakriti Tayalia, from the Department of Biosciences and Bioengineering at the IIT Bombay

"Without enough healthy cells, you cannot test them properly or use them for therapy," she added.

To better mimic the body's natural environment, Tayalia's team worked with a specific type of scaffold made using a process called electrospinning. These electrospun scaffolds look like thin mats made of very fine fibres, similar to a dense fishing net.

The team grew Jurkat T-cells (a human cell line grown and used in the laboratory to study T-cell biology, cancer, and HIV) inside electrospun scaffolds made from a material called polycaprolactone.

Under a microscope, the researchers observed that the cells actively moved into the scaffold and became tightly lodged between the fibres.

Further, the research showed that collecting the cells using trypsin, an enzyme, led to higher cell death.

In contrast, cells recovered with accutase, a milder enzyme, survived in greater numbers and behaved more like healthy T-cells. They formed clusters, an essential step before T-cells divide, and continued to grow well after recovery.

"Harsh treatments to cells, using enzymes such as trypsin, can damage key surface proteins needed for immune signalling and activation, reducing the cell's therapeutic usefulness. Accutase appears mild enough to avoid this problem," Tayalia said.

The study's findings, published in the journal Biomaterials Science, could help laboratories use such scaffolds when preparing cells for therapies such as CAR T-cell treatment.

"If we want these advanced therapies to reach patients, every step matters. How we grow cells, and how we retrieve them, can make a real difference," Tayalia said.

- IANS

Share this article:

Reader Comments

P
Priya S
Amazing work! My uncle is undergoing treatment and the cost is astronomical. If this can make therapies like CAR T-cell more efficient and potentially cheaper, it will be a godsend for so many Indian families.
D
David E
As someone in biotech, the shift from trypsin to accutase for sensitive cell recovery is a significant, practical finding. Kudos to Prof. Tayalia's team for focusing on these crucial, often overlooked, process details.
R
Rohit P
Fantastic news! But a respectful criticism: we read about these breakthroughs often. The real test is how quickly this moves from the lab in a journal to actual hospitals. Hope the system supports fast-tracking this.
S
Shreya B
Using a scaffold that mimics the body's environment is such a smart approach. It's like giving the cells a familiar home to grow in before their big fight. More power to our scientists! 🙏
M
Michael C
The global research community will take note of this. Improving cell viability post-recovery is a major hurdle in immunotherapy manufacturing. A simpler, gentler method from IIT-B could have worldwide impact.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50